# Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

> **NCT01203722** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 87 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cytoxan
- **RADIATION:** Total Body Irradiation
- **PROCEDURE:** Allogeneic Blood or Marrow Transplant
- **PROCEDURE:** Peripheral Blood Stem Cell Transplant
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01203722
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203722, "Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01203722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*